Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models

[1]  A. Judge,et al.  siRNA and innate immunity. , 2009, Oligonucleotides.

[2]  D. Scherman,et al.  How to make siRNA lipoplexes efficient? Add a DNA cargo. , 2009, Biochimica et biophysica acta.

[3]  A. Judge,et al.  Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. , 2008, Human gene therapy.

[4]  B. Pitard,et al.  Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma , 2010 .

[5]  D. Haussecker,et al.  The business of RNAi therapeutics. , 2008, Human gene therapy.

[6]  J. Harborth,et al.  RNAi therapeutics: an update on delivery. , 2008, Current opinion in molecular therapeutics.

[7]  A. D. Fougerolles.  Delivery vehicles for small interfering RNA in vivo. , 2008 .

[8]  J. Chirgwin,et al.  Skeletal metastases: Decreasing tumor burden by targeting the bone microenvironment , 2007, Journal of cellular biochemistry.

[9]  Zeng-peng Li,et al.  Vector‐based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo , 2007, Cancer science.

[10]  P. Gao,et al.  Inhibiting Proliferation and Enhancing Chemosensitivity to Taxanes in Osteosarcoma Cells by RNA Interference-Mediated Downregulation of Stathmin Expression , 2007, Molecular medicine.

[11]  J. Chirgwin,et al.  Molecular Biology of Bone Metastasis , 2007, Molecular Cancer Therapeutics.

[12]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[13]  E. Schwarz,et al.  Clinical development of anti-RANKL therapy , 2007, Arthritis research & therapy.

[14]  F. Gouin,et al.  Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies , 2007, Expert review of anticancer therapy.

[15]  P. Picci.  Osteosarcoma (Osteogenic sarcoma) , 2007, Orphanet journal of rare diseases.

[16]  D. Scherman,et al.  Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. , 2006, Arthritis and rheumatism.

[17]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[18]  T. Wu,et al.  Prospects of RNA interference therapy for cancer , 2006, Gene Therapy.

[19]  M. Woodle,et al.  Harnessing in vivo siRNA delivery for drug discovery and therapeutic development , 2006, Drug Discovery Today.

[20]  Mark E. Davis,et al.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.

[21]  M. Hung,et al.  Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  J. Thiery,et al.  Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. , 2005, Bone.

[23]  J. Thiery,et al.  A New Experimental Rat Model of Osteosarcoma Established by Intrafemoral Tumor Cell Inoculation, Useful for Biology and Therapy Investigations , 2005, Tumor Biology.

[24]  C. Colombeix,et al.  Downregulation of Osteoblast Markers and Induction of the Glial Fibrillary Acidic Protein by Oncostatin M in Osteosarcoma Cells Require PKCδ and STAT3 , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  W. Dougall,et al.  Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. , 2003, Cancer research.

[26]  D. Baltimore,et al.  Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[28]  Kathryn L. Parsley,et al.  High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter , 2002 .

[29]  I. Holen,et al.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. , 2001, Blood.

[30]  J. Michaeli,et al.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Ferrari,et al.  Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  P. Kostenuik,et al.  Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. , 2001, Cancer research.

[33]  Paul J. Williams,et al.  Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. , 2001, Cancer research.

[34]  T. Koshino,et al.  Predictive value of serum immunosuppressive acidic protein for lung metastasis after amputation of murine osteosarcoma of the lower limb. , 2000, Cancer letters.

[35]  E. Holmes,et al.  Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  B. Klein,et al.  [An experimental model of osteosarcomas in rats ]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[37]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[38]  T. Ochiya,et al.  Local and systemic delivery of siRNAs for oligonucleotide therapy. , 2009, Methods in molecular biology.

[39]  D. Heath,et al.  An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. , 2007, Cancer research.

[40]  A. Aigner,et al.  RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. , 2006, Human gene therapy.

[41]  Kathryn L. Parsley,et al.  High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. , 2002, Human gene therapy.

[42]  G. Rosen,et al.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. , 1977, Archives of pathology & laboratory medicine.